Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer

Eva Ciruelos • 15 Sep 2024
ESMO 2024
Breast Cancer Abemaciclib Elacestrant
ELECTRA

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, comments on the rationale and design of the ELECTRA trial (NCT05386108) of elacestrant plus abemaciclib in patients with ER+, HER2-, ESR1-mutant metastatic breast cancer (mBC). Phase Ib focuses on determining the recommended dose, while Phase II evaluates efficacy, particularly in patients with brain metastases. Early safety data suggests manageable side effects with no Grade 4 events or severe diarrhea reported. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Ciruelos

ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
0:42
ELECTRA: novel combinations for HR-positive breast cancer with CNS metastases
Eva Ciruelos • 15 Sep 2024
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
1:33
DESTINY-Breast12: enhancing outcomes for HR+/HER2+ patients with brain metastases
Eva Ciruelos • 15 Sep 2024
Global collaboration in biomarker-driven clinical trials at ESMO 2024
1:03
Global collaboration in biomarker-driven clinical trials at ESMO 2024
Eva Ciruelos • 15 Sep 2024
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
0:44
PATRICIA: Phase II study of palbociclib, trastuzumab, and endocrine therapy in HER2+ advanced BC
Eva Ciruelos • 31 May 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals